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A B S T R A C T   
Cataract is the leading cause of blindness worldwide. Congenital or paediatric cataract can result in permanent 
visual impairment or blindness even with best attempts at treatment. A significant proportion of paediatric 
cataract has a genetic cause. Therefore, identifying the genes that lead to cataract formation is essential for 
understanding the pathological process of inherited paediatric cataract as well as to the development of new 
therapies. Despite clear progress in genomics technologies, verification of the biological effects of newly iden-
tified candidate genes and variants is still challenging. Here, we provide a step-by-step pipeline to evaluate 
cataract candidate genes in F0 zebrafish using CRISPR-Cas9 ribonucleoprotein complexes (RNP). Detailed de-
scriptions of CRISPR-Cas9 RNP design and formulation, microinjection, optimization of CRISPR-Cas9 RNP re-
agent dose and delivery route, editing efficacy analysis as well as cataract formation evaluation are included. 
Following this protocol, any cataract candidates can be readily and efficiently evaluated within 2 weeks using 
basic laboratory supplies.   
1. Introduction 
Cataract is an opacity of the transparent crystalline lens in the eye 
that interferes with the path and refraction of light to the retina. It is the 
principal cause of reversible visual impairment or blindness worldwide 
[1]. While cataract in adults is usually treatable with access to surgery, 
congenital or paediatric cataract can lead to life-long irreversible vision 
impairment or blindness, despite best attempts at treatment. A signifi-
cant proportion of paediatric cataract is inherited and it often occurs 
alongside other syndromic features. Identifying the causative genes for 
inherited paediatric cataract can improve diagnostic accuracy through 
facilitating genetic testing. Gene identification can also improve un-
derstanding of the molecular mechanisms underlying cataractogenesis 
which may facilitate the development of medical therapy and individ-
ualized treatment [2]. So far, more than 40 genes have been linked to 
congenital or early-onset cataract [3–5] and they account for 60–70% of 
children with the disease [6–8]. However, significant challenges exist 
for identifying additional genes. Genome sequencing technologies are 
able to identify candidate variants, but validating these genes in mul-
tiple families is increasingly difficult for rare genetic causes of disease. 
Medium to high throughput techniques for evaluating the role of 
candidate genes in cataract formation are required. 
These human cataract candidate genes can be verified in animal 
models. Gene knockout models that display cataract formation provide 
strong evidence that a candidate gene is important in lens biology and 
cataract development. Several animal models have been used in cataract 
research, including mice, rats, rabbits, dogs, and zebrafish. However, the 
relatively small number of offspring and long generation period limit the 
application of mammalian models. In contrast, zebrafish (Danio rerio) 
become an outstanding model system due to a number of advantages. 
Their rapid development and simple husbandry enable the generation of 
large numbers of fish for genetic research work from a single mating. 
Zebrafish embryos develop externally and remain transparent for the 
first few days of development, providing technical advantages for em-
bryo microinjection. The eyes of the embryos are relatively large [9] and 
become functional by 3 days-post-fertilization (dpf) [10], allowing for 
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the observation of lens morphology at an early stage. The genome of 
zebrafish has been sequenced and annotated. Around 70% of human 
genes have functional orthologs in zebrafish [11]. This high level of 
homology to humans means that most human genes can be interrogated 
in zebrafish and the functions of those genes are largely similar between 
the two species. 
Clustered regularly interspaced short palindromic repeat (CRISPR)- 
Cas9 nuclease system has become a widely used targeted gene editing 
technology in zebrafish models. Its advantages over other methods such 
as zinc finger nucleases (ZFNs) and transcription activator-like effector 
nucleases (TALENs) include easy design processes and rapid synthesis of 
reagents. Morpholinos (MOs) have been used extensively for temporary 
knockdown of genes in zebrafish, but CRISPR-Cas9 provides a perma-
nent genetic modification with relatively low off-target effects. The 
system is comprised of guide RNA (gRNA) and Cas9 nuclease, which are 
combined to form a ribonucleoprotein (RNP) complex. The gRNA con-
sists of a target-specific CRISPR RNA (crRNA) and a universal trans- 
activating RNA (tracrRNA). The crRNA is designed to be complemen-
tary to the target DNA site, a 20 base pair sequence next to a protospacer 
adjacent motif (PAM) [12]. The gRNA forms a complex with the specific 
target site, directing the Cas9 nuclease to that locus. Once at the 
appropriate site, Cas9 nuclease can induce double-strand breaks (DSB), 
triggering non-homologous end joining (NHEJ) to repair the break. The 
error-prone NHEJ can produce small insertions or deletions between the 
end of the broken DNA strands, resulting in efficient mutagenesis 
[12–14]. 
Although many articles have described disease modelling in zebra-
fish, specific protocols for evaluation of cataracts in CRISPR-Cas9 edited 
zebrafish have not been reported. In this article, we provide a rapid and 
highly efficient method for evaluating cataract candidates in F0 zebra-
fish using CRISPR-Cas9 RNP. Detailed pipelines of CRISPR-Cas9 RNP 
design and formulation, microinjection, dose and delivery route opti-
mization of CRISPR-Cas9 RNP, editing efficacy analysis as well as 
cataract formation evaluation are included. 
2. Overview 
To better describe the pipeline of using CRISPR-Cas9 RNP to evaluate 
cataract genes in F0 zebrafish, we use HTR1F (5-hydroxytryptamine 
receptor 1F) as an example cataract candidate gene to illustrate the 
methods applied in this article. The HTR1F protein is a G-protein 
coupled serotonin receptor. Serotonin is crucial in lens transparency 
[15] and increased serotonin level has been shown to lead to lens 
opacities in rats [16]. The data presented in Section 4.4 and lens images 
shown in Section 4.5.2 were generated from HTR1F knockout experi-
ments. Fig. 1 illustrates the overall experimental workflow. 
3. Materials 
3.1. Reagents and equipment 
The reagents and equipment utilized in this protocol are summarized 
in Table 1 and Table 2. 
3.1.1. Reagent setup 
3.1.1.1. E2 embryo media with methylene blue. The 0.5x E2 with 0.5 mg/ 
l Methylene Blue working solution was prepared following the Zebrafish 
International Resource Center (ZIRC) protocol: https://zebrafish. 
org/wiki/protocols/nursery. The final concentrations of E2 media 
components are: 7.5 mM NaCl, 0.25 mM KCl, 0.5 mM MgSO4, 75 μM 
KH2PO4, 25 μM Na2HPO4, 0.5 mM CaCl2, and 0.35 mM NaHCO3. 
3.1.1.2. 1x PTU (200 µM) egg water. Add 0.076 g PTU (1-phenyl-2- 
thiourea) to 50 ml autoclaved Milli-Q water to prepare a 50x PTU 
(10,000 μM) stock solution. Store the 50x PTU stock solution at room 
temperature. Prepare fresh 1x PTU (200 μM) egg water each time as 
needed by diluting 50x PTU stock solution 50 times with E2 embryo 
media with Methylene Blue. 
Fig. 1. Overview of the main steps of the cataract gene evaluation pipeline. Each step corresponds to a section of the protocol with the same title.  
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NOTE:  
• PTU is highly toxic by ingestion and is a skin sensitizer. Weigh and 
prepare the PTU in a fume hood and always have gloves on during 
use. 
3.1.1.3. Alt-R CRISPR-Cas9 crRNA, tracrRNA and Cas9 nuclease 
aliquots. The CRISPR oligos are usually received dehydrated. Resuspend 
the Alt-R CRISPR-Cas9 crRNA and tracrRNA in IDTE buffer to final 
concentrations of 100 μM each. Store the rehydrated CRISPR oligos and 
S.p.HiFi-Cas9 nucleases according to supplier instructions. At the time of 
these experiments, we aliquoted crRNA, tracrRNA and S.p.HiFi-Cas9 
Nuclease into 2 μl small stocks and stored at − 20 oC to reduce unnec-
essary freeze–thaw cycles. 
3.1.1.4. Cas9 working buffer (20 mM HEPES; 150 mM KCl, pH 7.5). Mix 
the following:  
Component Amount 
1 M HEPES buffer 300 μl 
KCl powder 0.168 g 
RNase-free H2O 14.7 ml 
Final volume 15 ml  
After KCl powder completely dissolves in the solution, aliquot the Cas9 
working buffer into 1 ml stocks and store at 4 ◦C. 
3.2. Zebrafish maintenance and breeding 
AB strain zebrafish (source: Zebrafish International Resource Center 
(ZIRC)) were housed in a circulating water system under standard 
conditions [17], with a daily cycle of 14 h light/10 h dark. Embryos were 
obtained from the natural pairwise spawns of the wildtype AB zebrafish 
and were collected and raised in an incubator at 28.5 ◦C in E2 media 
with Methylene Blue until 5 dpf. The animal research in this study was 
approved by the University of Tasmania Animal Ethics Committee 
(project number: A0017743) in accordance with the Australian National 
Health and Medical Research Council Code of Practice for the Care and 
Use of Animals for Scientific Purpose. 
4. Methods 
4.1. gRNA design and CRISPR-Cas9 RNP formulation 
4.1.1. gRNA design 
The first and most critical step is the design of gRNA. The editing 
efficiencies of each gRNA can vary greatly, thus a well-designed gRNA is 
essential for successful CRISPR-Cas9-based gene disruptions. It is worth 
noting that zebrafish frequently have more than one ortholog of human 
genes [11]. For example, the HTR1F gene has two orthologs in the 
zebrafish genome, HTR1Fa and HTR1Fb. Collect the genomic DNA 
sequence, transcripts and protein information of all the orthologs of your 
target gene before starting gRNA design. There are multiple zebrafish 
genomic resources including Zebrafish Information Network (ZFIN) 
(http://zfin.org/), Ensembl (http://www.ensembl. 
org/Danio_rerio/Info/Index), UCSC genome browser (https://genome. 
ucsc.edu/) and NCBI zebrafish genome (https://www.ncbi.nlm.nih. 
gov/). Several CRISPR design tools are available online, such as 
CHOPCHOP (https://chopchop.cbu.uib.no/), CRISPOR (http://crispor. 
tefor.net/) and E-CRISP (http://www.e-crisp.org/E-CRISP/). For be-
ginners we recommend CHOPCHOP, as it is simple and intuitive. Here 
we use CHOPCHOP as an example to explain the steps of gRNA design.  
1. Input the gene identifiers or genomic coordinates or paste the 
genomic sequence of your target gene into CHOPCHOP, specify the 
organism and CRISPR mode to be “Danio rerio (danRer11/GRCz11)” 
and “CRISPR-Cas9” “knock-out”. Under the “Options”, by default, 
the target region, PAM sequence and number of mismatches of pre-
dicted off-targets have been set to “coding region”, “NGG” and “up to 
3” respectively. These parameters can be adjusted according to in-
dividual needs. After setting, click “Find Target Sites!” to perform 
guide search.  
2. A list of candidate gRNAs with relevant information such as target 
sequence, genomic location, number and type of predicted off- 
targets, GC content and efficiency score should be displayed. 
Detailed information of predicted off-targets including location, 
number of mismatches, and sequence can be found by clicking on an 
individual guide. Based on this information, select suitable gRNAs 
according to the principles below:  
• Position. It is recommended that the target sites are located within 
the most upstream exon that is conserved across all target transcripts 
Table 1 
Reagents used in this protocol.  
Item Supplier Catalogue 
No. 
NaCl, KCl, MgSO4, KH2PO4, Na2HPO4, CaCl2, 
NaHCO3. KCl powder 
Sigma-Aldrich – 
Methylene Blue AQUASONIC PL084 
Alt-R® CRISPR-Cas9 crRNA IDT – 
Alt-R® CRISPR-Cas9 tracrRNA IDT 1072533 
Alt-R® S.p.HiFi Cas9 Nuclease V3 IDT 1081060 
IDTE pH 7.5 (1X TE Solution) IDT 11-01-02-02 
1 M HEPES buffer Sigma-Aldrich H3375 
Nuclease-Free Duplex buffer IDT 11-01-03-01 
PTU (1-phenyl-2-thiourea) Sigma-Aldrich P7629 
Tricaine methanesulfonate Glentham Life 
Sciences 
GE5936 
Phire Tissue Direct PCR Master Mix Thermo Scientific F170s 
Agarose powder Bioline BIO-41025 
TAE buffer (Tris-acetate-EDTA) (50X) Thermo Scientific B49 
HyperLadder™ 100 bp Meridian 
Bioscience 
BIO-33056 
AMPure XP beads Beckman Coulter A63880 
CleanSEQ Dye-Terminator Removal kit Beckman Coulter A29151 
BrilliantDye™ Terminator (v3.1) Cycle 
Sequencing kit 
NimaGen BRD3-1000 
BigDye™ Terminator v1.1 & v3.1 5X 
Sequencing Buffer 
Thermo Scientific 4336699 
Ethanol Sigma-Aldrich E7023  
Table 2 
Equipment required for this protocol.  
Item Supplier Catalogue No. 
Standard microcentrifuge tubes, 1.5 ml Labcon #3039-560- 
000 
RNase-free microfuge tubes, 1.5 ml Thermo Scientific AM12400 
Filtered sterile pipette tips Labcon – 
Desktop microcentrifuges Bioline Global SF7000 
Vortex mixer Ratek IC-VM1 
Block heater Ratek DBH200 
Capillary glass (1.0 mm × 0.58 mm × 10 
cm) 
Harvard Apparatus GC100F-10 
Micropipette puller Sutter Instrument P-87 
Pico-liter injector Warner 
Instruments 
PLI-10 
Petri dish NEST Scientific 752001 
Nunc™ glass base dish (27 mm) Thermo Scientific 150682 
Incubator Nüve EN025 
Stereomicroscope Olympus SZX16 
Inverted microscope Nikon Eclipse Ti 
S-Series compact USB 2.0 camera Mightex SCE-B013-U 
sCMOS camera Andor Zyla 4.2 PLUS 
Veriti™ 96-well Thermal cycler Applied 
Biosystems 
4375786 
PowerPac™ basic power supply Bio-Rad 1645050 
Magnetic plate ALAPAQUA A001322 
3500 Genetic Analyzer Thermo Scientific A27772  
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of the gene of interest. This is most likely to generate frameshift 
mutations and early termination of the protein sequence. Alterna-
tively, gRNAs can be designed to target exons encoding known 
functional protein domains. In this way, the protein function could 
be disrupted even with non-frameshift alleles. 
• Editing efficiency. Select gRNAs with the highest on-target effi-
ciency and the fewest predicted off-targets. Generally, guides with 
predicted off-targets containing three or fewer mismatches to the 
target sequence should be avoided [13]. When multiple gRNAs have 
similar on and off-target efficiencies, priority is given to gRNAs with 
off-target loci on chromosomes other than the one that the target 
gene resides, or in non-coding regions (e.g. intergenic) that are un-
likely to have impacts on gene expression.  
• Number. It has been shown that targeting a single locus in a coding 
region only generates biallelic loss-of-function alleles 44% of the 
time, however, targeting a coding region at two, three, or four in-
dependent loci generates biallelic loss of function variants 79%, 
93%, and 98% of the time respectively [14]. To increase the success 
rate of introducing mutations and producing loss of protein function, 
we recommend designing 2 to 4 gRNAs for each target gene. None-
theless, it is suggested the total number of gRNAs injected per em-
bryo does not exceed 8, otherwise it may affect the survival and 
development of zebrafish embryos as well as increase the off-target 
effects [14]. The exact number of gRNAs to be injected into the 
zebrafish embryo depends on which gene is being targeted, the 
number of orthologs of the target gene, and how many genes are to 
be targeted simultaneously.  
• GC% of the guide sequence. A previous study has identified that 
gRNAs with over 50% GC content exhibit high mutagenesis activity 
[18].  
3. Order CRISPR oligos. The fully functional gRNA consists of the 
target-specific crRNA (designed above) and the tracrRNA with a 
universal sequence. The two components can be ordered pre- 
synthesized into the gRNA which can provide greater stability for 
challenging experimental conditions. Alternatively, for greater flex-
ibility, they can be ordered individually and assembled in house. 
NOTE:  
• The gRNA target sequences should be verified by Sanger sequencing 
in the strain of fish to be used in your experiment. It is possible, 
depending on the strain and source of the fish, that polymorphisms 
are present compared to the reference used to design the gRNAs. 
Even a single base mismatch can significantly reduce the targeting 
efficiency of the CRISPR system [19].  
• To eliminate the interference caused by CRISPR protein as well as 
injection-induced defects, it is necessary to involve a negative control 
in the experiments. gRNA against a non-existent gene in the zebrafish 
genome such as LacZ, a gene of E. coli, can be designed as a negative 
control. Align the target sequence of your negative control to the 
zebrafish genome to make sure there is no target in the zebrafish, and 
check the predicted off-targets of the negative control to avoid tar-
geting your gene of interest. 
4.1.2. CRISPR-Cas9 RNP formulation 
Two approaches have been commonly used to construct the CRISPR- 
Cas9 system for in vivo microinjection. Early methods co-inject gRNA 
and Cas9 mRNA into zebrafish embryos. With the proliferation of 
CRISPR-Cas9 reagents and suppliers, the more handy and cost-effective 
way is to directly deliver gRNA and Cas9 protein as RNP complex. 
Compared to mRNA-mediated delivery, RNP has the advantages of high 
stability, fast onset, and more importantly, by skipping the transcription 
process, it is likely to reduce genetic mosaicism due to Cas9 expression 
delay [20,21]. The protocol below used the Alt-R CRISPR-Cas9 system to 
synthesize CRISPR-Cas9 RNP and has been adapted from instructions 
provided by IDT (online instructions: Zebrafish embryo microinjection: 
Ribonucleoprotein delivery using the Alt-R CRISPR-Cas9 System).  
1. On the day of injection, thaw crRNA, tracrRNA and HiFi-Cas9 
nuclease stocks at room temperature.  
2. Preheat the heat block to 95 ◦C.  
3. Prepare 9 μM gRNA working solution by mixing the following 
components:   
Component Volume (μl) 
100 μM Alt-R® CRISPR-Cas9 crRNA 0.9 
100 μM Alt-R® CRISPR-Cas9 tracrRNA 0.9 
Nuclease-Free Duplex buffer 8.2 
Final volume 10  
In the case of multiple crRNAs, mix the crRNAs equally while keeping 
the total amount of crRNAs constant. The volumes provided here are the 
optimized results generated in our experiments (see Section 4.3). The 
user can adjust the volumes as required.  
4. Heat gRNA working solution at 95 ◦C for 5 min.  
5. Remove the working solution from the heat block and leave on the 
benchtop to cool to room temperature.  
6. Reset the heat block to 37 ◦C.  
7. Prepare 1.5 μg/μl Cas9 protein working solution. Mix the following 
reagents by flicking the tube and spin down briefly. Do not vortex.   
Component Volume (μl) 
10ug/ul Alt-R® S.p.HiFi Cas9 Nuclease V3 1.5 
Cas9 working buffer 8.5 
Final volume 10  
The volumes provided here are the optimized results generated in our 
experiments (see Section 4.3). The user can adjust the volumes as 
required. 
8. Assemble the CRISPR-Cas9 RNP complexes. For each experi-
mental group, combine 3 μl of 9 μM gRNA working solution with 
3 μl of 1.5 μg/μl Cas9 protein working solution. Mix the reagents 
by flicking the tube and spin down briefly. Do not vortex.  
9. Incubate the CRISPR-Cas9 RNP complexes at 37 ◦C for 10 min.  
10. Remove the CRISPR-Cas9 RNP complexes from the heat block 
and leave on the benchtop to cool to room temperature. 
NOTE:  
• Keep the whole process RNase-free. Clean work surfaces with RNase- 
inactivating solution, handle all materials with gloves and use 
RNase-free tips and tubes.  
• In this protocol we used HiFi Cas9 nuclease, which has significantly 
reduced off-target effects compare to wildtype S.p.Cas9 nuclease 
[22]. 
4.2. Microinjection 
Two possible delivery strategies can be applied in embryo microin-
jection: inject into the single cell or the yolk sac. In theory, cell injections 
are more likely to induce gene editing and increase the chance of editing 
both alleles simultaneously. However, it is technically challenging and 
time-consuming, limiting the number of embryos that can be injected in 
a single experiment. In comparison, yolk injections are high throughput, 
enabling an increased number of injected embryos to be achieved in one 
sitting. Additionally, yolk injections have been shown to have similar 
mutagenesis efficiencies to single-cell injections, with four times the 
D. Zhao et al.                                                                                                                                                                                                                                    
Methods xxx (xxxx) xxx
5
reagent dose [23].  
1. The afternoon before scheduled injection, set up zebrafish in 
breeding tanks and separate the males and females with dividers. We 
use two males to three females to increase the number of fertilised 
eggs produced for injection.  
2. On the morning of injection, pull out the dividers and allow the fish 
to spawn naturally. After approximately 10–15 min, collect the 
embryos and inject 1 nl of the CRISPR-Cas9 RNP into the cell of each 
one-cell stage embryo or 4 nl into the yolk sac instead. Use forceps to 
gently remove the embryos that have divided past the single-cell 
stage or fail to be injected. Save uninjected embryos from each 
clutch as controls.  
3. Incubate both injected and uninjected embryos at 28.5 ◦C in E2 
media with Methylene Blue in petri dishes. After 4–6 h, remove 
unfertilized or dead eggs, refresh the E2 media and record the 
number of surviving embryos. From 24hpf, raise the embryos in 1x 
PTU egg water to suppress pigment formation. Change the 1x PTU 
egg water twice a day as well as remove any dead embryos. Check 
and record the survival and dysmorphic rates. The injected larvae 
can be assessed for cataract and collected for editing efficiency 
analysis at 4dpf. 
NOTE:  
• Inject embryos as soon as possible and not beyond the one-cell stage. 
Early injection maximizes editing and reduces the genetic mosai-
cism, making the subsequent evaluation of editing efficiency easier.  
• It is recommended to line up and orient the embryos before injection. 
This can speed up the injection process when performing cell in-
jections, and avoids accidentally injecting the relatively large 
amount of CRISPR-Cas9 RNP (4 nl) into the cell when performing 
yolk injections.  
• The injection should be a single smooth motion. Do not adjust the 
orientation of the needle in the embryo. After injecting the RNP 
complexes, gently withdraw the needle and avoid tear out of the 
cytoplasm or yolk sac.  
• Power calculations should be performed to determine the minimum 
number of injected embryos required for statistical analysis. Inject 
more embryos than required to allow for natural attrition of early 
embryos. The number can be based on the survival rate calculated 
from optimization experiments.  
• In general, more than 50% of the embryos in the injected group are 
expected to show normal development similar to the uninjected 
siblings.  
• High levels of embryo death may be caused by excessive reagent 
concentration or may indicate that the target gene is essential for 
embryo survival. Repeat injections with a decreased reagent 
concentration.  
• Cloudy yolk sacs in surviving embryos likely indicate infection. Rinse 
the embryos carefully with E2 media prior to injection to remove any 
debris. Timely removal of dead embryos also helps to maintain the 
health of remaining embryos. 
4.3. Optimization of dose and delivery route of CRISPR-Cas9 RNP 
To achieve the optimal editing efficiency with minimum disruption 
to the development of the zebrafish embryo, we used gRNA targeting 
tyrosinase (tyr) gene to optimize the dose and delivery route of CRISPR- 
Cas9 RNPs. Knockout of the tyr gene results in pigmentation defects, 
which can be easily observed as early as 2 dpf (Fig. 2A) and quantita-
tively analyzed by measuring the pigment areas on the retina and the 
body of the injected zebrafish (Figure S1). tyr-gRNA is commercially 
available from IDT, or it can be designed by the user through the web- 
based CRISPR design tools. In the initial dose optimization process, 
the reagents were injected into the cell of one-cell-stage embryos at a 
fixed volume of 1 nl. We first tested a range of gRNA concentrations from 
0.5 μM to 13.5 μM, while keeping Cas9 nuclease at 0.75 μg/μl. A sig-
nificant reduction of pigmentation in the retina and body were observed 
in 4.5 μM and 13.5 μM gRNA-injected zebrafish (Fig. 2B and C). How-
ever, no statistical difference in pigment loss was found between 4.5 μM 
and 13.5 μM gRNA-injected zebrafish (retina: p = 0.9427; body: p =
0.9356). We then applied 4.5 μM and 13.5 μM gRNA to examine the 
effect of varying Cas9 concentration at 0.75 μg/μl or 1 μg/μl. In all 
experimental conditions that tested in the Cas9 concentration optimi-
zation, we observed significant pigment loss on both retina and body in 
the injected groups compared with the uninjected group (Fig. 2D and E), 
indicating high mutagenesis load. Although there were no significant 
differences in pigment loss between the injected groups in the optimi-
zation of Cas9 concentration (data not shown), the combination of 4.5 
μM gRNA and 0.75 μg/μl Cas9 nuclease presented with the highest 
survival rates (93%, 57 of 61 injected embryos). We therefore set the 
concentration of gRNA and Cas9 nuclease to be 4.5 μM and 0.75 μg/μl. 
We next used this condition to determine the delivery route. With the 
identical concentration of gRNA and Cas9 nuclease, we compared the 
pigment loss of injecting 1 nl of CRISPR-Cas9 RNP into the cell (Fig. 3A) 
and 4 nl into the yolk (Fig. 3B) of one-cell stage embryos. Our data 
showed that yolk injections had significantly higher body pigment loss 
(Fig. 3D, p = 0.042) and slightly higher survival rate (cell: 73%, 19 of 26 
injected embryos; yolk: 88%, 30 of 34 injected embryos) than cell in-
jections. In addition, considering the simple operation and high 
throughput of yolk injection, we chose to perform yolk injections in all 
subsequent experiments. 
4.4. Analysis of editing efficacy in F0 embryos: 
According to the principles described in Section 4.1.1, we designed 4 
gRNAs targeting different locations of HTR1Fa exon 2 and HTR1Fb exon 
1 respectively (Figure S2 and S3, Table S1). We first injected embryos 
with individual gRNAs and analyzed the editing efficiency. A detailed 
protocol of the single gRNA editing efficacy analysis is presented below. 
To improve consistency and convenience, we employed Phire Tissue 
Direct PCR Master Mix kit in the target region amplification step.  
1. Collect 5 larvae from each gRNA injected group at 4pdf, amplify the 
gRNA target region of individual larvae using the Phire Tissue Direct 
PCR Master Mix kit according to the manufacturer’s instructions.  
2. After PCR, inspect the PCR products on a 2% (w/v) gel to confirm 
that the target region has been amplified correctly, then Sanger 
sequence the amplicons.  
3. Upload the Sanger sequencing data (AB1 file) of both experimental 
and uninjected wildtype samples to the free online CRISPR analysis 
tool — Inference of CRISPR Edits (ICE) (https://www.synthego. 
com/products/bioinformatics/crispr-analysis) and specify the 
guide sequence. Once all the samples have been uploaded, click 
“Analyze” to perform the CRISPR editing efficiency analysis. 
The 8 designed gRNAs displayed various editing efficiencies, with 
the average indel percentage of individual embryos ranging from 53.4% 
to 88.4% (Fig. 4). We next pooled all 8 gRNAs at equal concentrations 
and co-injected the gRNA mixture with Cas9 nuclease into the embryos. 
Although a high survival rate was observed (87%, 68 of 78 injected 
embryos), a high dysmorphic rate (54%, 20 of 37 imaged embryos) was 
also observed in the injected embryos, suggesting 8 gRNAs may be too 
toxic to the development of embryos. We then injected CRISPR-Cas9 
RNPs carrying a mixture of the two most efficient gRNAs of both 
HTR1F orthologs into the embryos. The four-gRNA injected embryos 
showed a similar survival rate (78%, 58 of 74 injected embryos) to the 
eight-gRNA ones, but the dysmorphic rate (12%, 7 of 58 imaged em-
bryos) decreased dramatically to an acceptable level. 
NOTE: 
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Fig. 2. CRISPR-Cas9 RNP dose optimization. A. 
Zebrafish embryos at 2dpf. Embryos injected with 
CRISPR-Cas9 RNP against tyr gene (bottom) had 
observable pigment loss compare to uninjected 
wildtype zebrafish (top). B and C. Optimization of tyr 
gRNA concentration (UI: n = 11, 0.5 μM: n = 9, 1.5 
μM: n = 9, 4.5 μM: n = 16, 13.5 μM: n = 6). D and E. 
Optimization of Cas9 concentration (UI: n = 16, 4.5 
μM/0.75 μg/μl: n = 57, 4.5 μM/1μg/μl: n = 33, 13.5 
μM/0.75 μg/μl: n = 9, 13.5 μM/1μg/μl: n = 11). The 
pigment areas on the retina (B, D) and body (C, E) of 
zebrafish injected with a series of different concen-
trations of tyr gRNA or Cas9 were measured and 
compared (UI: uninjected; **p < 0.01, ***p < 0.001, 
****p < 0.0001; ns: not significant; one-way ANOVA 
and Tukey’s multiple comparisons test; Mean ±
SEM).   
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• Alternative methods for assessing genome editing include T7E1 assay 
[24], high-resolution melting analysis (HRMA) [25], heteroduplex 
mobility assay (HMA) [26], CRISPR-STAT assay [27], and next- 
generation sequencing (NGS) [28].  
• In the case of multi-guide-induced complex editing, we recommend 
applying NGS for editing efficacy analysis. ICE cannot clearly 
distinguish between noise and sample signal less than 5%, cannot 
detect deletions >150 bp for a multi-guide experiment, and can only 
analyze up to 3 gRNAs for the multi-guide knockout.  
• When amplifying the target region to detect mutagenesis activities 
that are induced by multiple gRNAs, properly design primer pairs to 
capture all gRNA target sites in a single amplicon, otherwise de-
letions generated between targets will remove primer binding sites 
and prevent PCR based amplification. 
4.5. Evaluation of cataract formation by microscope imaging 
4.5.1. Imaging  
1. On the fourth day after injection, anesthetize the larvae in tricaine 
(300 mg/l) for 1–2 min.  
2. Transfer a single larva to a glass base dish (27 mm diameter).  
3. Take whole-embryo images to record the gross morphology of the 
larvae. Our lab uses an SZX16 zoom stereomicroscope with Mightex 
S-Series compact USB 2.0 camera and SSClassicCamera software.  
4. Mount the larva in 0.5% (w/v) agarose and quickly orient it to a 
position in which the lens can be viewed directly through the bottom 
of the dish before the agarose hardens. 
5. Photograph the lens of the mounted larva using Differential Inter-
ference Contrast (DIC) microscopy settings with a Ti live cell mi-
croscope, Zyla 4.2 PLUS sCMOS camera and NIS-Elements AR 
acquisition software (or equivalent). Label the images with the fish 
number, experiment group and the time of imaging. 
NOTE:  
• Keep the melted agarose at approximately 40 ◦C, avoiding too high 
or too low temperatures. High temperatures will damage the larva, 
while low temperatures will cause the agarose to set too quickly, 
without allowing enough time to orient the larva.  
• Remove as much liquid as possible from the larva before mounting to 
prevent the larva from floating in the liquid and not being fixed.  
• Carefully wipe the glass bottom of the dish every time before 
mounting the larva, as any dirt or droplets on the dish bottom will be 
photographed into the lens images and interfere with the subsequent 
assessment of cataract.  
• Position the larva with one eye facing and touching the bottom of the 
dish. Avoid bubbles or agarose between the larva eye and the dish 
bottom, which will create artefacts or blur the lens image, making 
cataract assessment difficult. 
4.5.2. Cataract assessment 
The lens images were used to determine the cataract status of each 
fish. There are currently no standard criteria for the characterization of 
cataracts in zebrafish models. The difficulties in cataract assessment of 
zebrafish are mainly focused on the identification of normal developing 
Fig. 3. CRISPR-Cas9 RNP delivery route optimization. A and B. Illustrations of cell injection (A) and yolk injection (B). The zebrafish embryos were cell-injected (n =
19) or yolk-injected (n = 30) with tyr RNP. The pigment areas on the retina (C) and body (D) of zebrafish in the cell injection group and yolk injection group were 
measured and compared. (*p < 0.05, ns: not significant; unpaired two-tailed t-test; Mean ± SEM). 
Fig. 4. Editing efficiency analysis for individual gRNA. 5 injected larvae were randomly selected at 4dpf from each gRNA injected group, and the target region of 
individual embryos was amplified and analyzed for indel percentage. 
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lenses and artefacts from real cataracts. We reviewed the literature on 
the developing zebrafish lens morphology [29–33] as well as studies of 
cataract in zebrafish models [32,33], and reviewed the lens images 
produced from wildtype (uninjected) embryos from our experiments to 
understand the morphology of normal developing zebrafish lens. We 
then generated a detailed cataract assessment and scoring criteria for 
zebrafish models based on more than 700 lens images obtained from our 
experiments (Fig. 5 and Fig. 6).  
1. Crop lens images in ImageJ [34] to display only the lens region of the 
eye to avoid calling bias based on the phenotype of surrounding 
ocular features. 
Fig. 5. Zebrafish cataract assessment criteria (pitting).  
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2. Collate all images into a single group-set and perform blinding using 
a random number generator, to randomise and reassign image 
identification numbers. 
3. Provide the blinded data to two researchers who should indepen-
dently assess and score the images based on the standard images in 
Fig. 5 and Fig. 6 and descriptions below.  
• Pitting. Described as a dot-shaped depression on the surface of the 
lens. The pits can be diffused or aggregated in the central lens. Where 
pits exist, the uniform and smooth structure of the lens is destroyed.   
Catagory Description 
Pitting = No/ cataract = No Can be:  
• Developmental pitting (Fig. 5A and B). The pits 
are mostly fine and spread over the outer lens. 
They are undegraded organelles. The central lens 
is clear and uniform.  
• Artefacts (Fig. 5C and D). High reflective pits 
with very round and regular shape or pits with 
blurred edges are considered to be artefacts. The 
central lens is clear and uniform. 
Pitting=?/ cataract = No Can be:  
• Unclear pits (Fig. 5E and F), few in number in the 
centre of the lens. The rest of the lens is smooth 
and uniform.  
• Clear pits, but too few to be sure (Fig. 5G and H). 
There are one or two clear pits in the centre of the 
lens. The rest of the lens is smooth and uniform. 
Pitting = Yes/ cataract = Yes 
(mild, score = 1) 
Can be:  
• A small number of clear pits, enough to be 
confident (Fig. 5I and J). The pits are located in 
the central lens rather than the outer lens.  
• Pits may be blurred, but are numerous in the 
central lens (Fig. 5K and L). This may be caused 
by loss of focus during imaging. 
Pitting = Yes/ cataract = Yes 
(moderate, score = 2) 
Significant pits (Fig. 5M-P). Can be seen all over the 
lens or cluster in the central lens. 
Pitting = Yes/ cataract = Yes 
(severe, score = 3) 
Significant pits, deep or high density (Fig. 5Q-T). 
Seriously obstruct the visual pathway.    
• Central mass. The centre of the lens presents as an irregular shape 
protrusion, which is significantly different from the rest of the lens. 
The central lens has lost its smooth and high regular structure.   
Catagory Description 
Central mass = No/ cataract =
No 
The centre of the lens may seem to bulge out 
compared to the rest of the lens, but it is smooth, 
uniform and has a regular shape (Fig. 6A-D). The 
outer lens is uniform and well developed. This 
could be an optical illusion caused by light or the 
different depths of the lens that had been 
captured during imaging. 
Central mass = Yes/ cataract =
Yes (mild, score = 1) 
The central lens lost its round shape and become 
“flower-shape” (Fig. 6E). The outer lens is mostly 
uniform and well developed. The “flower-shape” 
is presumed to be the outline of the original, 
undifferentiated cells in the lens nucleus. 
Central mass = Yes/ cataract =
Yes (moderate, score = 2) 
The central lens is abnormal, lost its round shape 
and smooth, uniform texture (Fig. 6F). In the lens 
nucleus, original, undifferentiated cells appear to 
be visible, meanwhile the outer lens is well 
developed. 
Central mass = Yes/ cataract =
Yes (severe, score = 3) 
The central lens is significantly abnormal, 
completely lost its regular, smooth texture 
(Fig. 6G and H).    
4. Any images with differing cataract classifications should then be 
assessed by a third researcher to break the tie, prior to unblinding. 
NOTE:  
• Frequently, regular concentric circles (Fig. 7A and B) or irregular 
“ring-like” (Fig. 7C-E) or “wave-like” structures (Fig. 7F-H) can be 
observed in the lenses with the central area uniform and smooth. 
They are believed to be maturing lens fiber cells rather than devel-
opmental cataracts, as we observed similar structures in the lens 
images of developing wildtype zebrafish that showed in the literature 
[29–33]. No cataract is called unless there is obvious disruption to 
make the “flower-shape” that is highlighted in the central mass 
category. 
5. Discussion 
Gene identification for inherited paediatric cataract continues and 
has accelerated in recent years with the advent of whole exome and 
Fig. 6. Zebrafish cataract assessment criteria (central mass).  
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genome sequencing to complement family-based linkage approaches. 
However, functional validation of these genes remains a bottleneck in 
the discovery pipeline. The rapid development of genome engineering 
techniques, particularly CRISPR-Cas9, has greatly promoted reverse 
genetic screening, making routine functional assessment possible. Here 
we provide a step-by-step protocol as well as hands-on tips for rapid and 
highly efficient evaluation of cataract candidate genes in F0 zebrafish 
using a CRISPR-Cas9 RNP strategy. We generated zebrafish cataract 
assessment criteria, which to our knowledge, are the first systematic, 
definitive cataract assessment criteria for the zebrafish model. This 
protocol can be used to develop zebrafish models for in-depth study of 
specific genes, or to rapidly assess the cataract forming potential of 
multiple genes. With gene discovery in human patients and their fam-
ilies routinely employing genome-wide approaches, it is not uncommon 
to identify several plausible candidate genes. Ideally, similar variants in 
those genes would be found in additional affected families, however, 
that process can take many years until just the right family makes it into 
a research or diagnostic program. The use of a rapid zebrafish-based 
functional validation protocol can provide valuable evidence for the 
role of candidate genes in cataract formation. 
A major concern of the F0-based gene functional evaluation is the ge-
netic mosaicism in the injected fish. The variety of unpredictable indels 
induced by CRISPR-Cas9 complicate phenotypic analysis. However, some 
recent studies have demonstrated that well-designed CRISPR-Cas9 with 
mutagenesis efficiency approaching saturation can induce almost fully 
penetrant loss-of-function phenotypes with low off-targets, faithfully 
simulating the null mutants in F0 embryos [21,23,35,36]. Several critical 
strategies were applied in our protocol to maximize mutagenesis effi-
ciency. Firstly, we provide comprehensive gRNA design instructions and 
detailed injection condition optimization pipeline to obtain appropriately 
designed guides and optimal injections, thus lay the foundation for high 
mutagenesis efficiency. In our hands, five of the eight tested gRNAs had an 
editing efficiency of over 80%, with the maximum editing efficiency 
reached 88.4%. Secondly, by designing gRNAs targeting multiple sites of a 
single gene and injecting these gRNAs simultaneously, the mutagenicity is 
further improved with the increase of the probability of including efficient 
guides and loss-of-function deletions. Finally, we applied CRISPR-Cas9 
RNP, which is more mutagenic compare to the CRISPR-Cas9 mRNA com-
plex [18,21], to achieve saturating mutagenesis. After successful evalua-
tion following this protocol, any promising cataract candidates can be 
further confirmed in stable germline-transmitted mutant lines. 
Another vital factor for successful cataract candidate gene evaluation 
is the accurate identification of cataract phenotypes in the fish lens. 
Because of its simplicity and directness, lens images of live embryos are 
widely used for phenotypic assessment of zebrafish cataract models. 
However, there is a lack of standardized reference material available to 
assess zebrafish cataract development. Multiple factors can interfere 
with the cataract assessment. Developmental delays are frequently 
observed in CRISPR-Cas9 injected embryos, and the presence of devel-
oping lens fiber cells makes it difficult to distinguish real cataracts. A 
similar study reported that cataracts detected at 3dpf were absent at 
4dpf [37]. It cannot be ruled out that the phenotypes observed are the 
manifestation of immature lenses and not developmental cataracts. 
Therefore, we suggest analysing the phenotype at 4dpf or even 5dpf, to 
ensure the lens is of sufficient maturity to obtain reliable phenotypes. 
Artefact is another confounding factor. Based on our experience, lesions 
with a very round and regular shape, highly reflective dots or pitting 
with blurred edges are considered artefacts. In addition, CRISPR injec-
tion itself is possible to lead to non-specific lens lesions. In this situation, 
the false positive phenotypes can be effectively eliminated by the use of 
a properly designed negative control such as LacZ. In our assessment 
criteria, we defined cataract in the early zebrafish larvae by character-
izing defects that lead to gross changes in lens morphology observable 
by brightfield microscopy with further classification by severity. Ex-
amples of false positives are also given. Our use of single fish strain (AB) 
and a mild phenotype observed with our chosen candidate gene are the 
major limitations of our cataract assessment criteria to date. These 
should continue to be developed to apply to additional strains which 
may have different developmental rates and to account for more severe 
cataract that may be observed with different genes. 
In summary, we report a simple CRISPR-Cas9 RNP based method for 
rapid and efficient evaluation of cataract candidate genes in F0 zebrafish. 
Compared with traditional functional analysis strategies that need to 
establish stable mutant lines, our protocol creates significant labour- and 
time-savings. In addition, we also generated detailed criteria to allow 
standardized assessment of the lens phenotype using brightfield imaging 
and provide reference images for accurate and rigorous phenotypic 
analysis. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
Fig. 7. Normal developing lens images with maturing lens fiber cells.  
D. Zhao et al.                                                                                                                                                                                                                                    
Methods xxx (xxxx) xxx
11
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgement 
We thank Elise Yeaman for technical support and maintenance of 
zebrafish lines. 
Funding 
This work was supported by the National Health and Medical 
Research Council (NHMRC) of Australia [grants GNT1185477, 
GNT1059954 and GNT1116360]. Duran Zhao was supported by a 
Health Tasmania Graduate Research Scholarship. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ymeth.2020.12.004. 
References 
[1] S.R. Flaxman, R.R. Bourne, S. Resnikoff, P. Ackland, T. Braithwaite, M.V. Cicinelli, 
et al., Global causes of blindness and distance vision impairment 1990–2020: a 
systematic review and meta-analysis, Lancet Global Health 5 (12) (2017) 
e1221–e1234. 
[2] L. Zhao, X.-J. Chen, J. Zhu, Y.-B. Xi, X. Yang, L.-D. Hu, et al., Lanosterol reverses 
protein aggregation in cataracts, Nature 523 (7562) (2015) 607–611. 
[3] J.F. Hejtmancik, Congenital cataracts and their molecular genetics, Semin. Cell 
Dev. Biol. 19 (2008) 134–149. 
[4] A. Shiels, T.M. Bennett, J.F. Hejtmancik, Cat-Map: putting cataract on the map, 
Mol. Vision 16 (2010) 2007. 
[5] A. Shiels, J.F. Hejtmancik, Mutations and mechanisms in congenital and age- 
related cataracts, Exp. Eye Res. 156 (2017) 95–102. 
[6] R.L. Gillespie, J. O’Sullivan, J. Ashworth, S. Bhaskar, S. Williams, S. Biswas, et al., 
Personalized diagnosis and management of congenital cataract by next-generation 
sequencing, Ophthalmology 121 (11) (2014), 2124–2137.e2. 
[7] S. Javadiyan, J.E. Craig, E. Souzeau, S. Sharma, K.M. Lower, D.A. Mackey, et al., 
High-throughput genetic screening of 51 pediatric cataract genes identifies 
causative mutations in inherited pediatric cataract in South Eastern Australia, G3: 
Genes, Genomes, Genetics 7 (10) (2017) 3257–3268. 
[8] A.S. Ma, J.R. Grigg, G. Ho, I. Prokudin, E. Farnsworth, K. Holman, et al., Sporadic 
and familial congenital cataracts: Mutational spectrum and new diagnoses using 
next-generation sequencing, Hum. Mutat. 37 (4) (2016) 371–384. 
[9] P. Goldsmith, Modelling eye diseases in zebrafish, NeuroReport 12 (13) (2001) 
A73–A77. 
[10] G.J. Lieschke, P.D. Currie, Animal models of human disease: zebrafish swim into 
view, Nat. Rev. Genet. 8 (5) (2007) 353. 
[11] K. Howe, M.D. Clark, C.F. Torroja, J. Torrance, C. Berthelot, M. Muffato, et al., The 
zebrafish reference genome sequence and its relationship to the human genome, 
Nature 496 (7446) (2013) 498–503. 
[12] W.Y. Hwang, Y. Fu, D. Reyon, M.L. Maeder, S.Q. Tsai, J.D. Sander, et al., Efficient 
genome editing in zebrafish using a CRISPR-Cas system, Nat. Biotechnol. 31 (3) 
(2013) 227. 
[13] N. Chang, C. Sun, L. Gao, D. Zhu, X. Xu, X. Zhu, et al., Genome editing with RNA- 
guided Cas9 nuclease in zebrafish embryos, Cell Res. 23 (4) (2013) 465–472. 
[14] P.D. Hsu, E.S. Lander, F. Zhang, Development and applications of CRISPR-Cas9 for 
genome engineering, Cell 157 (6) (2014) 1262–1278. 
[15] S. Vivekanandan, M.F. Lou, Evidence for the presence of phosphoinositide cycle 
and its involvement in cellular signal transduction in the rabbit lens, Curr. Eye Res. 
8 (1) (1989) 101–111. 
[16] R. Boerrigter, J. Siertsema, I. Kema, Serotonin (5-HT) and the rat’s eye, Doc. 
Ophthalmol. 82 (1–2) (1992) 141–150. 
[17] M. Westerfield, The zebrafish book: a guide for the laboratory use of zebrafish, 
2000 http://zfin.org/zf_info/zfbook/zfbk.html. 
[18] J.A. Gagnon, E. Valen, S.B. Thyme, P. Huang, L. Ahkmetova, A. Pauli, et al., 
Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and 
large-scale assessment of single-guide RNAs, PLoS ONE 9 (5) (2014), e98186. 
[19] S. Lessard, L. Francioli, J. Alfoldi, J.C. Tardif, P.T. Ellinor, D.G. MacArthur, et al., 
Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at 
therapeutically implicated loci, Proc. Natl. Acad. Sci. U S A 114 (52) (2017) 
E11257–E11266. 
[20] S. Chen, S. Sun, D. Moonen, C. Lee, A.-Y.-F. Lee, D.V. Schaffer, et al., CRISPR- 
READI: Efficient generation of knockin mice by CRISPR RNP electroporation and 
AAV donor infection, Cell Rep. 27 (13) (2019). 
[21] A. Burger, H. Lindsay, A. Felker, C. Hess, C. Anders, E. Chiavacci, et al., 
Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein 
complexes, Development 143 (11) (2016) 2025–2037. 
[22] B.P. Kleinstiver, V. Pattanayak, M.S. Prew, S.Q. Tsai, N.T. Nguyen, Z. Zheng, et al., 
High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target 
effects, Nature 529 (7587) (2016) 490–495. 
[23] R.S. Wu, I.I. Lam, H. Clay, D.N. Duong, R.C. Deo, S.R. Coughlin, A rapid method for 
directed gene knockout for screening in G0 Zebrafish, Dev. Cell 46 (1) (2018) 
112–25 e4. 
[24] M.C. Huang, W.C. Cheong, L.S. Lim, M.H. Li, A simple, high sensitivity mutation 
screening using Ampligase mediated T7 endonuclease I and Surveyor nuclease with 
microfluidic capillary electrophoresis, Electrophoresis 33 (5) (2012) 788–796. 
[25] H.R. Thomas, S.M. Percival, B.K. Yoder, J.M. Parant, High-throughput genome 
editing and phenotyping facilitated by high resolution melting curve analysis, PLoS 
ONE 9 (12) (2014), e114632. 
[26] S. Ota, Y. Hisano, M. Muraki, K. Hoshijima, T.J. Dahlem, D.J. Grunwald, et al., 
Efficient identification of TALEN-mediated genome modifications using 
heteroduplex mobility assays, Genes Cells 18 (6) (2013) 450–458. 
[27] G.K. Varshney, B. Carrington, W. Pei, K. Bishop, Z. Chen, C. Fan, et al., A high- 
throughput functional genomics workflow based on CRISPR/Cas9-mediated 
targeted mutagenesis in zebrafish, Nat. Protoc. 11 (12) (2016) 2357–2375. 
[28] A.N. Shah, C.F. Davey, A.C. Whitebirch, A.C. Miller, C.B. Moens, Rapid reverse 
genetic screening using CRISPR in zebrafish, Nat. Methods 12 (6) (2015) 535–540. 
[29] T.M. Greiling, J.I. Clark, Early lens development in the zebrafish: a three- 
dimensional time-lapse analysis, Dev. Dyn.: An Official Publication of the Am. 
Assoc. Anatomists 238 (9) (2009) 2254–2265. 
[30] R. Dahm, H.B. Schonthaler, A.S. Soehn, J. Van Marle, G.F. Vrensen, Development 
and adult morphology of the eye lens in the zebrafish, Exp. Eye Res. 85 (1) (2007) 
74–89. 
[31] T.M. Greiling, J.I. Clark, New insights into the mechanism of lens development 
using zebra fish. International review of cell and molecular biology, Elsevier 
(2012) 1–61. 
[32] N. Gath, J.M. Gross, Zebrafish mab21l2 mutants possess severe defects in optic cup 
morphogenesis, lens and cornea development, Dev. Dyn. 248 (7) (2019) 514–529. 
[33] K. Taler, O. Weiss, S. Rotem-Bamberger, A.M. Rubinstein, P. Seritrakul, J.M. Gross, 
et al., Lysyl hydroxylase 3 is required for normal lens capsule formation and 
maintenance of lens epithelium integrity and fate, Dev. Biol. 458 (2) (2020) 
177–188. 
[34] J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, et 
al., Fiji: an open-source platform for biological-image analysis, Nat. Methods 9 (7) 
(2012) 676–682. 
[35] C.J. Watson, A.T. Monstad-Rios, R.M. Bhimani, C. Gistelinck, A. Willaert, 
P. Coucke, et al., Phenomics-Based Quantification of CRISPR-Induced Mosaicism in 
Zebrafish, Cell Syst. (2020). 
[36] K. Hoshijima, M.J. Jurynec, D.K. Shaw, A.M. Jacobi, M.A. Behlke, D.J. Grunwald, 
Highly efficient CRISPR-Cas9-based methods for generating deletion mutations and 
F0 embryos that lack gene function in zebrafish, Dev. Cell 51 (5) (2019). 
[37] I. Vorontsova, I. Gehring, J.E. Hall, T.F. Schilling, Aqp0a Regulates Suture Stability 
in the Zebrafish Lens, Invest. Ophthalmol. Vis. Sci. 59 (7) (2018) 2869–2879. 
D. Zhao et al.                                                                                                                                                                                                                                    
